GLP-1 Weight-Loss Search Interest by Gender
Review August 2025 vs. August 2026: Women search for GLP-1 weight-loss treatments 2.5× more than men — a gap that held firm in both 2025 and 2026
Info
- Sample size
- n = 15,288
- Data date
- August 2025 vs. August 2026
- Segment
- male, female
- Platform
- Search
- Market
- Germany
Analysis
Women's GLP-1 search-interest rate runs roughly 2.5 times higher than men's in Germany — a structural gap that persisted unchanged from August 2025 to August 2026, and predates the imminent oral Wegovy launch.
A gender skew mirrored in clinical uptake
The pattern is consistent with real-world prescription data. Research on oral semaglutide uptake in other EU markets found the oral form was more frequently used by younger females — aligning with the demographic profile of tablet-specific searchers in Germany, 68% of whom were female. Ahead of the 1 September 2026 Wegovy pill launch in German pharmacies, this persistent gender gap signals that women will likely be the primary adopters of the new oral format — both because they are the dominant research audience now, and because needle aversion may be more prevalent as a stated barrier. The age-group breakdown behind these aggregate rates is explored in GLP-1 search interest by age group.
This analysis is based on public segment data. For deeper cuts, use our Enterprise interface.
Methodology
The search-interest rate for each gender is the share of male and female German adult online searchers active in August 2025 or August 2026 who queried GLP-1 weight-loss terms (Wegovy, Ozempic, Saxenda, Mounjaro, semaglutide, tirzepatide, and related terms). Rates are calibrated to the German adult online population (18+) and weighted to reflect demographic composition. The gender comparison is the robust finding; absolute percentages are panel-internal rates.
These insights are based on the Datapods Panel. Our data comes exclusively from users who are compensated for their anonymity. Become part of the panel & earn from your data